

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**WUXI XDC CAYMAN INC.**

**藥明合聯生物技術有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2268)**

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING  
HELD ON DECEMBER 12, 2025**

The Board announces that at the EGM held on December 12, 2025, all proposed resolutions as set out in the notice of the EGM were duly passed by the shareholders of the Company by way of poll.

The board (the “**Board**”) of directors (the “**Directors**”) of WuXi XDC Cayman Inc. 藥明合聯生物技術有限公司\* (the “**Company**”) announces that at the extraordinary general meeting of the Company (the “**EGM**”) held on December 12, 2025, all proposed resolutions as set out in the notice of the EGM were duly passed by the shareholders of the Company by way of poll. Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the circular dated November 26, 2025 (the “**Circular**”). The executive Directors, Dr. Jincai Li, Mr. Jerry Jingwei Zhang and Mr. Xiaojie Xi; and the non-executive Director, Dr. Zhisheng Chen attended the EGM either in person or by electronic means.

The poll results taken at the EGM were as follows:

ORDINARY RESOLUTIONS		Number of Votes (Approximate %)	
		For	Against
1.	(i) the revised maximum service fees from the Company and/or its subsidiaries to WuXi Biologics and/or its subsidiaries for the transactions contemplated under the Existing Antibodies Master Services Agreement in the amount of RMB3,000.00 million for the year ending December 31, 2025, and the transactions thereunder be and are hereby approved, ratified and confirmed;	155,580,099 (100%)	0 (0%)
	(ii) the antibodies master services framework agreement dated September 22, 2025 (the “ <b>New Antibodies Master Services Agreement</b> ”) (a copy of which is tabled at the Meeting and marked “A” and signed by the chairman of the Meeting for identification purposes) entered between the Company and WuXi Biologics, and all the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;	155,580,099 (100%)	0 (0%)
	(iii) the annual caps with respect to the New Antibodies Master Services Agreement for each of the years ending December 31, 2026, 2027 and 2028 be and are hereby approved;	155,580,099 (100%)	0 (0%)
	(iv) the payload-linkers master services framework agreement dated September 2, 2025 (the “ <b>New Payload-Linkers Master Services Agreement</b> ”) (a copy of which is tabled at the Meeting and marked “B” and signed by the chairman of the Meeting for identification purposes) entered between the Company and WuXi AppTec, and all the transactions contemplated thereunder be and are hereby approved, confirmed and ratified;	155,580,099 (100%)	0 (0%)
	(v) the annual caps with respect to the New Payload-Linkers Master Services Agreement for each of the years ending December 31, 2026, 2027 and 2028 be and are hereby approved; and	155,580,099 (100%)	0 (0%)

ORDINARY RESOLUTIONS		Number of Votes (Approximate %)	
		For	Against
	(vi) any Director or any other person authorized by the Directors be and is hereby authorized for and on behalf of the Company to do all acts and things and execute any agreements, deeds, instruments and any other documents, under hand or under seal, or make such arrangement as he/she may determine to be appropriate, necessary or desirable to give effect to or in connection with the Revised Annual Cap, the renewal of the Existing CCT Agreements, the adoption of annual caps contemplated thereunder and the transactions thereunder and, subject to and in accordance with the applicable laws and regulations, to approve and make such immaterial variation, amendment, supplement or waiver of immaterial matters relating thereto in the interests of the Company and its shareholders as a whole.	155,580,099 (100%)	0 (0%)

As at the date of the EGM, the total number of shares of the Company in issue was 1,255,126,193 Shares. As stated in the Circular, (i) WuXi Biologics (a controlling shareholder of the Company) and Dr. Zhisheng Chen (a director of WuXi Biologics and the Company) and their respective associates holding Shares were required to abstain and they had abstained from voting on the resolutions numbered 1(i), (ii) and (iii) in respect of approving the Revised Annual Cap, the renewal of the Existing Antibodies Master Services Agreement and the transactions contemplated thereunder proposed at the EGM; and (ii) WuXi AppTec (a substantial shareholder of the Company) and its respective associates were required to abstain and they had abstained from voting on the resolutions numbered 1(iv) and (v) in respect of approving the renewal of the Existing Payload-Linkers Master Services Agreement and the transactions contemplated thereunder at the EGM.

To the best knowledge and belief of the Company, after making all reasonable enquiries, as at the date of the EGM, (i) WuXi Biologics and its associates hold 635,484,500 Shares; (ii) Dr. Zhisheng Chen and his associates hold 418,878 Shares; and (iii) WuXi AppTec and its associates hold 232,900,000 Shares.

Accordingly, as at the date of the EGM, the total number of Shares entitling the holders to attend and vote on resolutions numbered 1(i), (ii) and (iii) were 619,222,815 Shares, the total number of Shares entitling the holders to attend and vote on resolutions numbered 1(iv) and (v) were 1,022,226,193 Shares. The Company did not hold any treasury Shares or repurchased Shares pending cancellation.

Save as disclosed above, there were no restrictions on any shareholders of the Company to cast votes on any of the resolutions proposed at the EGM. No shareholder of the Company has stated his/her/its intention in the Company's Circular to vote against or to abstain from voting on any of the resolutions at the EGM.

The Company's Hong Kong branch share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the EGM.

By order of the Board  
**WuXi XDC Cayman Inc.**

**Dr. Jincal LI**  
*Executive Director and Chief Executive Officer*

Hong Kong, December 12, 2025

*As at the date of this announcement, the board of directors of the Company comprises (i) Dr. Jincal LI, Mr. Jerry Jingwei ZHANG and Mr. Xiaojie XI as executive directors; (ii) Dr. Zhisheng CHEN, Dr. Jijie GU and Ms. Ming SHI as non-executive directors; and (iii) Dr. Ulf GRAWUNDER, Mr. Kenneth Walton HITCHNER III and Mr. Hao ZHOU as independent non-executive directors.*

\* *For identification purpose only*